Free Trial

Assertio Q1 2024 Earnings Report

Assertio logo
$0.68 +0.01 (+1.49%)
As of 04/3/2025 04:00 PM Eastern

Assertio EPS Results

Actual EPS
$0.03
Consensus EPS
-$0.01
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Assertio Revenue Results

Actual Revenue
$32.45 million
Expected Revenue
$28.93 million
Beat/Miss
Beat by +$3.52 million
YoY Revenue Growth
N/A

Assertio Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Assertio Earnings Headlines

This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Assertio price target lowered to $1.75 from $2.15 at Alliance Global
Assertio Therapeutics (ASRT) Gets a Buy from Lake Street
See More Assertio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Assertio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assertio and other key companies, straight to your email.

About Assertio

Assertio (NASDAQ:ASRT), a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

View Assertio Profile

More Earnings Resources from MarketBeat